Products for Research Use Only
RegisterLogin

Elimusertib

CAT: 0804-HY-101566-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-101566-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib has anti-tumor activity[1][2]. Elimusertib can be used for the research of solid tumors and lymphomas[3].
CAS Number
1876467-74-1
Product Name Alternative
BAY 1895344
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
ATM/ATR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BAY-1895344.html
Concentration
10mM
Purity
99.91
Solubility
DMSO : 5.4 mg/mL (ultrasonic)
Smiles
CN1N=CC=C1C2=C(C=CN=C3C4=CC=NN4)C3=NC(N5[C@H](C)COCC5)=C2
Molecular Formula
C20H21N7O
Molecular Weight
375.43
Precautions
H302, H315, H319, H335
References & Citations
[1]Ulrich T. Luecking, et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement.|[2]Antje Margret Wengner, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement|[3]Ulrich Lücking, et al. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem. 2020 Jul 9;63 (13) :7293-7325.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
ATR
Citation 01
Biochem Pharmacol. 2023 May:211:115494.|bioRxiv. 2025 Sep 30.|Cell Rep Med. 2025 May 6:102129.|EMBO Rep. 2024 Mar;25 (3) :1469-1489.|Exp Mol Med. 2025 Feb;57 (1) :167-183.|J Med Chem. 2024 Feb 22;67 (4) :2349-2368.|Mol Cell Biol. 2025;45 (3) :99-115.|Nat Commun. 2024 Oct 24;15 (1) :9195.|Research Square Preprint. 2023 Jun 9.|Research Square Preprint. 2023 May 17.|Research Square Preprint. 2023 Nov 20.|Cancer Res. 2022 Mar 15;82 (6) :1013-1024.|RSC Adv. 2025 Jun 16;15 (26) :20385-20396.

Alternative Products

CatalogName
BUP12371-01Elimusertib
T62102-01Elimusertib hydrochloride
333061Elimusertib free base
S9864-01Elimusertib (BAY-1895344)
C13574-5mgElimusertib (BAY-1895344) hydrochloride

Popular Products